SBI Securities Co. Ltd. Lowers Stake in Johnson & Johnson $JNJ

SBI Securities Co. Ltd. decreased its position in Johnson & Johnson (NYSE:JNJ) by 3.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 116,762 shares of the company’s stock after selling 4,281 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Johnson & Johnson were worth $21,650,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Evolution Wealth Management Inc. acquired a new position in shares of Johnson & Johnson in the second quarter valued at approximately $27,000. Clayton Financial Group LLC purchased a new position in Johnson & Johnson in the 3rd quarter valued at approximately $28,000. Semmax Financial Advisors Inc. increased its position in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares during the period. GFG Capital LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at $35,000. Finally, Compass Financial Services Inc boosted its holdings in Johnson & Johnson by 707.1% in the third quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock valued at $42,000 after purchasing an additional 198 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.5%

NYSE JNJ opened at $234.26 on Thursday. The firm’s fifty day moving average price is $212.27 and its 200 day moving average price is $193.02. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $235.83. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company has a market capitalization of $564.40 billion, a price-to-earnings ratio of 21.20, a price-to-earnings-growth ratio of 2.26 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.46. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. The company had revenue of $24.56 billion during the quarter, compared to the consensus estimate of $24.14 billion. During the same quarter in the prior year, the firm posted $2.04 earnings per share. Johnson & Johnson’s revenue for the quarter was up 9.1% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.2%. Johnson & Johnson’s payout ratio is currently 47.06%.

Analyst Ratings Changes

Several equities research analysts have weighed in on JNJ shares. UBS Group restated a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. Raymond James Financial boosted their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. Scotiabank reissued an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $250.00 target price on shares of Johnson & Johnson in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $233.73.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst upgrades and raised price targets are boosting investor sentiment — Bank of America raised its PT to $227 (from $221) and RBC raised its PT to $255 while keeping an Outperform rating, signaling confidence in JNJ’s outlook. BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 – Here’s Why RBC Raises Price Target on Johnson & Johnson to $255
• Positive Sentiment: Clinical and commercial oncology updates are underpinning the longer‑term earnings thesis — recent ERLEADA and DARZALEX FASPRO data/updates are framed as material to JNJ’s oncology growth, and commentary expects oncology sales to roughly double over time. That bolsters the case for faster revenue/earnings ramp. ERLEADA And DARZALEX FASPRO Updates Shape Johnson And Johnson Oncology Story Johnson & Johnson’s Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy?
• Positive Sentiment: Product and medtech momentum: JNJ MedTech announced Varipulse updates and a new ultrasound catheter, and ACUVUE launched a novel daily multifocal toric contact lens in the UK/Ireland — both moves expand near‑term commercial catalysts and diversify growth drivers outside pharma. Johnson & Johnson MedTech announces updates to Varipulse, new ultrasound catheter Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens
• Neutral Sentiment: Context piece: recent analysis highlights JNJ’s ~50% stock rally over the past nine months driven by improved earnings, product wins and legal progress — useful for sentiment context but not new company-specific catalyst. What’s Behind The 50% Surge In JNJ Stock?

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.